Tracking a Fast-Moving Disease: Longitudinal Markers, Monitoring, and Clinical Trial Endpoints in ALS

Rangariroyashe Hannah Chipika, Eoin Finegan, Stacey Li Hi Shing, Orla Hardiman, Peter Bede, Rangariroyashe Hannah Chipika, Eoin Finegan, Stacey Li Hi Shing, Orla Hardiman, Peter Bede

Abstract

Amyotrophic lateral sclerosis (ALS) encompasses a heterogeneous group of phenotypes with different progression rates, varying degree of extra-motor involvement and divergent progression patterns. The natural history of ALS is increasingly evaluated by large, multi-time point longitudinal studies, many of which now incorporate presymptomatic and post-mortem assessments. These studies not only have the potential to characterize patterns of anatomical propagation, molecular mechanisms of disease spread, but also to identify pragmatic monitoring markers. Sensitive markers of progressive neurodegenerative change are indispensable for clinical trials and individualized patient care. Biofluid markers, neuroimaging indices, electrophysiological markers, rating scales, questionnaires, and other disease-specific instruments have divergent sensitivity profiles. The discussion of candidate monitoring markers in ALS has a dual academic and clinical relevance, and is particularly timely given the increasing number of pharmacological trials. The objective of this paper is to provide a comprehensive and critical review of longitudinal studies in ALS, focusing on the sensitivity profile of established and emerging monitoring markers.

Keywords: amyotrophic lateral sclerosis; biomarkers; magnetic resonance imaging; motor neuron disease; neuroimaging.

References

    1. Katyal N, Govindarajan R. Shortcomings in the current amyotrophic lateral sclerosis trials and potential solutions for improvement. Front Neurol. (2017) 8:521. 10.3389/fneur.2017.00521
    1. Miller Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. (2002) 14:CD001447 10.1002/14651858.CD001447
    1. Al-Chalabi A, Jones A, Troakes C, King A, Al-Sarraj S, van den Berg LH. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol. (2012) 124:339–52. 10.1007/s00401-012-1022-4
    1. Menke RA, Korner S, Filippini N, Douaud G, Knight S, Talbot K, et al. . Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis. Brain. (2014) 137(Pt 9):2546–55. 10.1093/brain/awu162
    1. Eisen A, Kiernan M, Mitsumoto H, Swash M. Amyotrophic lateral sclerosis: a long preclinical period? J Neurol Neurosurg Psychiatry. (2014) 85:1232–8. 10.1136/jnnp-2013-307135
    1. Benatar M, Wuu J. Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology. (2012) 79:1732–9. 10.1212/WNL.0b013e31826e9b1d
    1. Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. (2014) 13:1127–38. 10.1016/S1474-4422(14)70129-2
    1. Beghi E, Chio A, Couratier P, Esteban J, Hardiman O, Logroscino G, et al. . The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler. (2011) 12:1–10. 10.3109/17482968.2010.502940
    1. de Carvalho M, Swash M. Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis? Arch Neurol. (2006) 63:557–60. 10.1001/archneur.63.4.557
    1. Schuster C, Elamin M, Hardiman O, Bede P. Presymptomatic and longitudinal neuroimaging in neurodegeneration–from snapshots to motion picture: a systematic review. J Neurol Neurosurg Psychiatry. (2015) 86:1089–96. 10.1136/jnnp-2014-309888
    1. Turner MR, Agosta F, Bede P, Govind V, Lule D, Verstraete E. Neuroimaging in amyotrophic lateral sclerosis. Biomark Med. (2012) 6:319–37. 10.2217/bmm.12.26
    1. Bede P, Hardiman O. Lessons of ALS imaging: pitfalls and future directions - a critical review. NeuroImage Clin. (2014) 4:436–43. 10.1016/j.nicl.2014.02.011
    1. Bowser R, Turner MR, Shefner J. Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. Nat Rev Neurol. (2011) 7:631–8. 10.1038/nrneurol.2011.151
    1. Bede P, Hardiman O. Longitudinal structural changes in ALS: a three time-point imaging study of white and gray matter degeneration. Amyotroph Lateral Scler Frontotemporal Degener. (2018) 19:232–41. 10.1080/21678421.2017.1407795
    1. Floeter MK, Danielian LE, Braun LE, Wu T. Longitudinal diffusion imaging across the C9orf72 clinical spectrum. J Neurol Neurosurg Psychiatry. (2018) 89:53–60. 10.1136/jnnp-2017-316799
    1. Kassubek J, Muller HP, Del Tredici K, Lule D, Gorges M, Braak H, et al. . Imaging the pathoanatomy of amyotrophic lateral sclerosis in vivo: targeting a propagation-based biological marker. J Neurol Neurosurg Psychiatry. (2018) 89:374–81. 10.1136/jnnp-2017-316365
    1. Stampfli P, Sommer S, Czell D, Kozerke S, Neuwirth C, Weber M, et al. . Investigation of neurodegenerative processes in amyotrophic lateral sclerosis using white matter fiber density. Clin Neuroradiol. (2018). 10.1007/s00062-018-0670-8. [Epub ahead of print].
    1. Baldaranov D, Khomenko A, Kobor I, Bogdahn U, Gorges M, Kassubek J, et al. . Longitudinal diffusion tensor imaging-based assessment of tract alterations: an application to amyotrophic lateral sclerosis. Front Hum Neurosci. (2017) 11:567. 10.3389/fnhum.2017.00567
    1. de Albuquerque M, Branco LM, Rezende TJ, de Andrade HM, Nucci A, Franca MC, Jr. Longitudinal evaluation of cerebral and spinal cord damage in Amyotrophic Lateral Sclerosis. NeuroImage Clin. (2017) 14:269–76. 10.1016/j.nicl.2017.01.024
    1. Menke RAL, Proudfoot M, Talbot K, Turner MR. The two-year progression of structural and functional cerebral MRI in amyotrophic lateral sclerosis. Neuroimage Clin. (2018) 17:953–61. 10.1016/j.nicl.2017.12.025
    1. Simon NG, Lagopoulos J, Paling S, Pfluger C, Park SB, Howells J, et al. . Peripheral nerve diffusion tensor imaging as a measure of disease progression in ALS. J Neurol. (2017) 264:882–90. 10.1007/s00415-017-8443-x
    1. Floeter MK, Bageac D, Danielian LE, Braun LE, Traynor BJ, Kwan JY. Longitudinal imaging in C9orf72 mutation carriers: relationship to phenotype. NeuroImage Clin. (2016) 12:1035–43. 10.1016/j.nicl.2016.10.014
    1. Schulthess I, Gorges M, Muller HP, Lule D, Del Tredici K, Ludolph AC, et al. . Functional connectivity changes resemble patterns of pTDP-43 pathology in amyotrophic lateral sclerosis. Sci Rep. (2016) 6:38391. 10.1038/srep38391
    1. McMillan CT, Russ J, Wood EM, Irwin DJ, Grossman M, McCluskey L, et al. . C9orf72 promoter hypermethylation is neuroprotective: neuroimaging and neuropathologic evidence. Neurology. (2015) 84:1622–30. 10.1212/WNL.0000000000001495
    1. Steinbach R, Loewe K, Kaufmann J, Machts J, Kollewe K, Petri S, et al. . Structural hallmarks of amyotrophic lateral sclerosis progression revealed by probabilistic fiber tractography. J Neurol. (2015) 262:2257–70. 10.1007/s00415-015-7841-1
    1. Westeneng H-J, Verstraete E, Walhout R, Schmidt R, Hendrikse J, Veldink JH, et al. . Subcortical structures in amyotrophic lateral sclerosis. Neurobiol Aging. (2015) 36:1075–82. 10.1016/j.neurobiolaging.2014.09.002
    1. Schuster C, Kasper E, Machts J, Bittner D, Kaufmann J, Benecke R, et al. . Longitudinal course of cortical thickness decline in amyotrophic lateral sclerosis. J Neurol. (2014) 261:1871–80. 10.1007/s00415-014-7426-4
    1. Stoppel CM, Vielhaber S, Eckart C, Machts J, Kaufmann J, Heinze HJ, et al. . Structural and functional hallmarks of amyotrophic lateral sclerosis progression in motor- and memory-related brain regions. NeuroImage Clin. (2014) 5:277–90. 10.1016/j.nicl.2014.07.007
    1. Verstraete E, Veldink JH, van den Berg LH, van den Heuvel MP. Structural brain network imaging shows expanding disconnection of the motor system in amyotrophic lateral sclerosis. Hum Brain Mapp. (2014) 35:1351–61. 10.1002/hbm.22258
    1. Ignjatovic A, Stevic Z, Lavrnic S, Dakovic M, Bacic G. Brain iron MRI: a biomarker for amyotrophic lateral sclerosis. J Magn Reson Imaging. (2013) 38:1472–9. 10.1002/jmri.24121
    1. Kwan JY, Meoded A, Danielian LE, Wu T, Floeter MK. Structural imaging differences and longitudinal changes in primary lateral sclerosis and amyotrophic lateral sclerosis. Neuroimage Clin. (2012) 2:151–60. 10.1016/j.nicl.2012.12.003
    1. Keil C, Prell T, Peschel T, Hartung V, Dengler R, Grosskreutz J. Longitudinal diffusion tensor imaging in amyotrophic lateral sclerosis. BMC Neurosci. (2012) 13:141. 10.1186/1471-2202-13-141
    1. Menke RA, Abraham I, Thiel CS, Filippini N, Knight S, Talbot K, et al. . Fractional anisotropy in the posterior limb of the internal capsule and prognosis in amyotrophic lateral sclerosis. Arch Neurol. (2012) 69:1493–9. 10.1001/archneurol.2012.1122
    1. Ichikawa H, Ohno H, Murakami H, Ohnaka Y, Kawamura M. Writing error may be a predictive sign for impending brain atrophy progression in amyotrophic lateral sclerosis: a preliminary study using X-ray computed tomography. Eur Neurol. (2011) 65:346–51. 10.1159/000328216
    1. van der Graaff MM, Sage CA, Caan MW, Akkerman EM, Lavini C, Majoie CB, et al. . Upper and extra-motoneuron involvement in early motoneuron disease: a diffusion tensor imaging study. Brain. (2011) 134(Pt 4):1211–28. 10.1093/brain/awr016
    1. Zhang Y, Schuff N, Woolley SC, Chiang GC, Boreta L, Laxamana J, et al. . Progression of white matter degeneration in amyotrophic lateral sclerosis: a diffusion tensor imaging study. Amyotroph Lateral Scler. (2011) 12:421–9. 10.3109/17482968.2011.593036
    1. Agosta F, Gorno-Tempini ML, Pagani E, Sala S, Caputo D, Perini M, et al. . Longitudinal assessment of grey matter contraction in amyotrophic lateral sclerosis: a tensor based morphometry study. Amyotroph Lateral Scler. (2009) 10:168–74. 10.1080/17482960802603841
    1. Agosta F, Rocca MA, Valsasina P, Sala S, Caputo D, Perini M, et al. . A longitudinal diffusion tensor MRI study of the cervical cord and brain in amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. (2009) 80:53–5. 10.1136/jnnp.2008.154252
    1. Avants B, Khan A, McCluskey L, Elman L, Grossman M. Longitudinal cortical atrophy in amyotrophic lateral sclerosis with frontotemporal dementia. Arch Neurol. (2009) 66:138–9. 10.1001/archneurol.2008.542
    1. Lule D, Diekmann V, Kassubek J, Kurt A, Birbaumer N, Ludolph AC, et al. . Cortical plasticity in amyotrophic lateral sclerosis: motor imagery and function. Neurorehabil Neural Repair. (2007) 21:518–26. 10.1177/1545968307300698
    1. Unrath A, Ludolph AC, Kassubek J. Brain metabolites in definite amyotrophic lateral sclerosis. A longitudinal proton magnetic resonance spectroscopy study. J Neurol. (2007) 254:1099–106. 10.1007/s00415-006-0495-2
    1. Suhy J, Miller RG, Rule R, Schuff N, Licht J, Dronsky V, et al. Early detection and longitudinal changes in amyotrophic lateral sclerosis by 1H MRSI. Neurology. (2002) 58:773–9. 10.1212/WNL.58.5.773
    1. Block W, Karitzky J, Träber F, Pohl C, Keller E, Mundegar RR, et al. . Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements. Arch Neurol. (1998) 55:931–6. 10.1001/archneur.55.7.931
    1. Irwin DJ, McMillan CT, Brettschneider J, Libon DJ, Powers J, Rascovsky K, et al. . Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. (2013) 84:163–9. 10.1136/jnnp-2012-303507
    1. Kolind S, Sharma R, Knight S, Johansen-Berg H, Talbot K, Turner MR. Myelin imaging in amyotrophic and primary lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. (2013) 14:562–73. 10.3109/21678421.2013.794843
    1. Verstraete E, Veldink JH, Hendrikse J, Schelhaas HJ, van den Heuvel MP, van den Berg LH. Structural MRI reveals cortical thinning in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. (2012) 83:383–8. 10.1136/jnnp-2011-300909
    1. Blain CR, Williams VC, Johnston C, Stanton BR, Ganesalingam J, Jarosz JM, et al. . A longitudinal study of diffusion tensor MRI in ALS. Amyotroph Lateral Scler. (2007) 8:348–55. 10.1080/17482960701548139
    1. Rule RR, Suhy J, Schuff N, Gelinas DF, Miller RG, Weiner MW. Reduced NAA in motor and non-motor brain regions in amyotrophic lateral sclerosis: a cross-sectional and longitudinal study. Amyotroph Lateral Scler Other Motor Neuron Disord. (2004) 5:141–9. 10.1080/14660820410017109
    1. Escorcio-Bezerra ML, Abrahao A, Santos-Neto D, de Oliveira Braga NI, Oliveira ASB, Manzano GM. Why averaging multiple MUNIX measures in the longitudinal assessment of patients with ALS? Clin Neurophysiol. (2017) 128:2392–6. 10.1016/j.clinph.2017.09.104
    1. de Carvalho M, Swash M. Fasciculation potentials and earliest changes in motor unit physiology in ALS. J Neurol Neurosurg Psychiatry. (2013) 84:963–8. 10.1136/jnnp-2012-304545
    1. Boekestein WA, Schelhaas HJ, van Putten MJ, Stegeman DF, Zwarts MJ, van Dijk JP. Motor unit number index (MUNIX) versus motor unit number estimation (MUNE): a direct comparison in a longitudinal study of ALS patients. Clin Neurophysiol. (2012) 123:1644–9. 10.1016/j.clinph.2012.01.004
    1. Cheah BC, Lin CS, Park SB, Vucic S, Krishnan AV, Kiernan MC. Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clin Neurophysiol. (2012) 123:2460–7. 10.1016/j.clinph.2012.06.020
    1. Ahn S-W, Kim J-E, Sung J-J, Lee K-W, Hong Y-H. Asymmetry of motor unit number estimate and its rate of decline in patients with amyotrophic lateral sclerosis. J Clin Neurophysiol. (2011) 28:528–32. 10.1097/WNP.0b013e318231c9e0
    1. Cheah BC, Vucic S, Krishnan AV, Boland RA, Kiernan MC. Neurophysiological index as a biomarker for ALS progression: validity of mixed effects models. Amyotroph Lateral Scler. (2011) 12:33–8. 10.3109/17482968.2010.531742
    1. de Carvalho M, Swash M. Sensitivity of electrophysiological tests for upper and lower motor neuron dysfunction in ALS: a six-month longitudinal study. Muscle Nerve. (2010) 41:208–11. 10.1002/mus.21495
    1. Neuwirth C, Nandedkar S, Stalberg E, Weber M. Motor unit number index (MUNIX): a novel neurophysiological technique to follow disease progression in amyotrophic lateral sclerosis. Muscle Nerve. (2010) 42:379–84. 10.1002/mus.21707
    1. Floyd AG, Yu QP, Piboolnurak P, Tang MX, Fang Y, Smith WA, et al. . Transcranial magnetic stimulation in ALS: utility of central motor conduction tests. Neurology. (2009) 72:498–504. 10.1212/01.wnl.0000341933.97883.a4
    1. Gooch CL, Pullman SL, Shungu DC, Ulug AM, Chan S, Gordon PH, et al. . Motor unit number estimation (MUNE) in diseases of the motor neuron: utility and comparative analysis in a multimodal biomarker study. Suppl Clin Neurophysiol. (2009) 60:153–62. 10.1016/S1567-424X(08)00015-9
    1. Liu XX, Zhang J, Zheng JY, Zhang S, Xu YS, Kang DX, et al. . Stratifying disease stages with different progression rates determined by electrophysiological tests in patients with amyotrophic lateral sclerosis. Muscle Nerve. (2009) 39:304–9. 10.1002/mus.21144
    1. Albrecht E, Kuntzer T. Number of Edb motor units estimated using an adapted multiple point stimulation method: normal values and longitudinal studies in ALS and peripheral neuropathies. Clin Neurophysiol. (2004) 115:557–63. 10.1016/j.clinph.2003.11.001
    1. Wang FC, Bouquiaux O, De Pasqua V, Delwaide PJ. Changes in motor unit numbers in patients with ALS: a longitudinal study using the adapted multiple point stimulation method. Amyotroph Lateral Scler Other Motor Neuron Disord. (2002) 3:31–8. 10.1080/146608202317576516
    1. Chan KM, Stashuk DW, Brown WF. A longitudinal study of the pathophysiological changes in single human thenar motor units in amyotrophic lateral sclerosis. Muscle Nerve. (1998) 21:1714–23.
    1. Felice KJ. A longitudinal study comparing thenar motor unit number estimates to other quantitative tests in patients with amyotrophic lateral sclerosis. Muscle Nerve. (1997) 20:179–85.
    1. Yuen EC, Olney RK. Longitudinal study of fiber density and motor unit number estimate in patients with amyotrophic lateral sclerosis. Neurology. (1997) 49:573–8. 10.1212/WNL.49.2.573
    1. Vucic S, Lin CS, Cheah BC, Murray J, Menon P, Krishnan AV, et al. . Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain. (2013) 136(Pt 5):1361–70. 10.1093/brain/awt085
    1. Aggarwal A, Nicholson G. Detection of preclinical motor neurone loss in SOD1 mutation carriers using motor unit number estimation. J Neurol Neurosurg Psychiatry. (2002) 73:199–201. 10.1136/jnnp.73.2.199
    1. Arasaki K, Kato Y, Hyodo A, Ushijima R, Tamaki M. Longitudinal study of functional spinal alpha motor neuron loss in amyotrophic lateral sclerosis. Muscle Nerve. (2002) 25:520–6. 10.1002/mus.10067
    1. de Carvalho M, Miranda PC, Luis ML, Ducla-Soares E. Cortical muscle representation in amyotrophic lateral sclerosis patients: changes with disease evolution. Muscle Nerve. (1999) 22:1684–92.
    1. Swash M, Schwartz MS. A longitudinal study of changes in motor units in motor neuron disease. J Neurol Sci. (1982) 56:185–97. 10.1016/0022-510X(82)90141-1
    1. Thakore NJ, Lapin BR, Pioro EP. Trajectories of impairment in amyotrophic lateral sclerosis: insights from the pooled resource open-access ALS clinical trials cohort. Muscle Nerve. (2018) 57:937–45. 10.1002/mus.26042
    1. Rooney J, Burke T, Vajda A, Heverin M, Hardiman O. What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. (2016) 88:381–5. 10.1136/jnnp-2016-314661
    1. The amyotrophic lateral sclerosis functional rating scale Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. Arch Neurol. (1996) 53:141–7. 10.1001/archneur.1996.00550020045014
    1. Floeter MK, Traynor BJ, Farren J, Braun LE, Tierney M, Wiggs EA, et al. . Disease progression in C9orf72 mutation carriers. Neurology. (2017) 89:234–41. 10.1212/WNL.0000000000004115
    1. Elamin M, Bede P, Byrne S, Jordan N, Gallagher L, Wynne B, et al. . Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology. (2013) 80:1590–7. 10.1212/WNL.0b013e31828f18ac
    1. Roberts-South A, Findlater K, Strong MJ, Orange JB. Longitudinal changes in discourse production in amyotrophic lateral sclerosis. Semin Speech Lang. (2012) 33:79–94. 10.1055/s-0031-1301165
    1. Duning T, Schiffbauer H, Warnecke T, Mohammadi S, Floel A, Kolpatzik K, et al. . G-CSF prevents the progression of structural disintegration of white matter tracts in amyotrophic lateral sclerosis: a pilot trial. PLoS ONE. (2011) 6:e17770. 10.1371/journal.pone.0017770
    1. Poletti B, Solca F, Carelli L, Faini A, Madotto F, Lafronza A, et al. . Cognitive-behavioral longitudinal assessment in ALS: the Italian Edinburgh Cognitive and Behavioral ALS screen (ECAS). Amyotroph Lateral Scler Frontotemporal Degener. (2018) 19:387–95. 10.1080/21678421.2018.1473443
    1. Xu Z, Alruwaili ARS, Henderson RD, McCombe PA. Screening for cognitive and behavioural impairment in amyotrophic lateral sclerosis: frequency of abnormality and effect on survival. J Neurol Sci. (2017) 376:16–23. 10.1016/j.jns.2017.02.061
    1. Gillingham SM, Yunusova Y, Ganda A, Rogaeva E, Black SE, Stuss DT, et al. . Assessing cognitive functioning in ALS: a focus on frontal lobe processes. Amyotroph Lateral Scler Frontotemporal Degener. (2017) 18:182–92. 10.1080/21678421.2016.1248977
    1. Mioshi E, Hsieh S, Caga J, Ramsey E, Chen K, Lillo P, et al. . A novel tool to detect behavioural symptoms in ALS. Amyotroph Lateral Scler Frontotemporal Degener. (2014) 15:298–304. 10.3109/21678421.2014.896927
    1. Jakobsson Larsson B, Ozanne AG, Nordin K, Nygren I. A prospective study of quality of life in amyotrophic lateral sclerosis patients. Acta Neurol Scand. (2017) 136:631–8. 10.1111/ane.12774
    1. Beck M, Giess R, Magnus T, Puls I, Reiners K, Toyka KV, et al. . Progressive sudomotor dysfunction in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. (2002) 73:68–70. 10.1136/jnnp.73.1.68
    1. Garruto RM, Plato CC, Yanagihara R, Fox K, Dutt J, Gajdusek DC, et al. . Bone mass in Guamanian patients with amyotrophic lateral sclerosis and parkinsonism-dementia. Am J Phys Anthropol. (1989) 80:107–13. 10.1002/ajpa.1330800112
    1. Ioannides ZA, Steyn FJ, Henderson RD, McCombe PA, Ngo ST. Anthropometric measures are not accurate predictors of fat mass in ALS. Amyotroph Lateral Scler Frontotemporal Degener. (2017) 18:486–91. 10.1080/21678421.2017.1317811
    1. Peter RS, Rosenbohm A, Dupuis L, Brehme T, Kassubek J, Rothenbacher D, et al. . Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry Swabia. Eur J Epidemiol. (2017) 32:901–8. 10.1007/s10654-017-0318-z
    1. Nunes G, Santos CA, Grunho M, Fonseca J. Enteral feeding through endoscopic gastrostomy in amyotrophic lateral sclerosis patients. Nutr Hosp. (2016) 33:561. 10.20960/nh.561
    1. Jablecki CK, Berry C, Leach J. Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve. (1989) 12:833–41. 10.1002/mus.880121008
    1. Andres PL, Allred MP, Stephens HE, Proffitt Bunnell M, Siener C, Macklin EA, et al. Fixed dynamometry is more sensitive than vital capacity or ALS rating scale. Muscle Nerve. (2017) 56:710–5. 10.1002/mus.25586
    1. de Bie E, Oskarsson B, Joyce NC, Nicorici A, Kurillo G, Han JJ. Longitudinal evaluation of upper extremity reachable workspace in ALS by Kinect sensor. Amyotroph Lateral Scler Frontotemporal Degener. (2017) 18:17–23. 10.1080/21678421.2016.1241278
    1. Shellikeri S, Green JR, Kulkarni M, Rong P, Martino R, Zinman L, et al. . Speech movement measures as markers of bulbar disease in amyotrophic lateral sclerosis. J Speech Lang Hear Res. (2016) 59:887–99. 10.1044/2016_JSLHR-S-15-0238
    1. Londral A, Pinto S, de Carvalho M. Markers for upper limb dysfunction in Amyotrophic Lateral Sclerosis using analysis of typing activity. Clin Neurophysiol. (2016) 127:925–31. 10.1016/j.clinph.2015.06.017
    1. Panitz S, Kornhuber M, Hanisch F. The checklist individual strength (CIS20-R) in patients with amyotrophic lateral sclerosis - a longitudinal study. Acta Neurol Scand. (2015) 131:372–80. 10.1111/ane.12349
    1. Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. . The PRO-ACT database: design, initial analyses, and predictive features. Neurology. (2014) 83:1719–25. 10.1212/WNL.0000000000000951
    1. Watanabe H, Atsuta N, Nakamura R, Hirakawa A, Watanabe H, Ito M, et al. . Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. (2015) 16:230–6. 10.3109/21678421.2014.990036
    1. Leonardis L, Dolenc Groselj L, Vidmar G. Factors related to respiration influencing survival and respiratory function in patients with amyotrophic lateral sclerosis: a retrospective study. Eur J Neurol. (2012) 19:1518–24. 10.1111/j.1468-1331.2012.03754.x
    1. Mahajan KR, Bach JR, Saporito L, Perez N. Diaphragm pacing and noninvasive respiratory management of amyotrophic lateral sclerosis/motor neuron disease. Muscle Nerve. (2012) 46:851–5. 10.1002/mus.23663
    1. Pinto S, Geraldes R, Vaz N, Pinto A, de Carvalho M. Changes of the phrenic nerve motor response in amyotrophic lateral sclerosis: longitudinal study. Clin Neurophysiol. (2009) 120:2082–5. 10.1016/j.clinph.2009.08.025
    1. Montes J, Cheng B, Diamond B, Doorish C, Mitsumoto H, Gordon PH. The Timed Up and Go test: predicting falls in ALS. Amyotroph Lateral Scler. (2007) 8:292–5. 10.1080/17482960701435931
    1. Vender RL, Mauger D, Walsh S, Alam S, Simmons Z. Respiratory systems abnormalities and clinical milestones for patients with amyotrophic lateral sclerosis with emphasis upon survival. Amyotroph Lateral Scler. (2007) 8:36–41. 10.1080/17482960600863951
    1. Wilson SR, Quantz MA, Strong MJ, Ahmad D. Increasing peak expiratory flow time in amyotrophic lateral sclerosis. Chest. (2005) 127:156–60. 10.1378/chest.127.1.156
    1. Poloni M, Mento SA, Mascherpa C, Ceroni M. Value of spirometric investigations in amyotrophic lateral sclerosis. Ital J Neurol Sci. (1983) 4:39–46. 10.1007/BF02043436
    1. Andersen TM, Sandnes A, Fondenes O, Nilsen RM, Tysnes OB, Heimdal JH, et al. . Laryngeal responses to mechanically assisted cough in progressing amyotrophic lateral sclerosis. Respir Care. (2018) 63:538–49. 10.4187/respcare.05924
    1. Quaranta VN, Carratu P, Damiani MF, Dragonieri S, Capozzolo A, Cassano A, et al. . The prognostic role of obstructive sleep apnea at the onset of amyotrophic lateral sclerosis. Neurodegener Dis. (2017) 17:14–21. 10.1159/000447560
    1. Proudfoot M, Menke RA, Sharma R, Berna CM, Hicks SL, Kennard C, et al. . Eye-tracking in amyotrophic lateral sclerosis: a longitudinal study of saccadic and cognitive tasks. Amyotroph Lateral Scler Frontotemporal Degener. (2015) 17:101–11. 10.3109/21678421.2015.1054292
    1. Lenglet T, Lacomblez L, Abitbol JL, Ludolph A, Mora JS, Robberecht W, et al. . A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol. (2014) 21:529–36. 10.1111/ene.12344
    1. Yamauchi R, Imai T, Tsuda E, Hozuki T, Yamamoto D, Shimohama S. Respiratory insufficiency with preserved diaphragmatic function in amyotrophic lateral sclerosis. Intern Med. (2014) 53:1325–31. 10.2169/internalmedicine.53.2326
    1. Mendoza M, Gelinas DF, Moore DH, Miller RG. A comparison of maximal inspiratory pressure and forced vital capacity as potential criteria for initiating non-invasive ventilation in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. (2007) 8:106–11. 10.1080/17482960601030188
    1. Marti-Fabregas J, Dourado M, Sanchis J, Miralda R, Pradas J, Illa I. Respiratory function deterioration is not time-linked with upper-limb onset in amyotrophic lateral sclerosis. Acta Neurol Scand. (1995) 92:261–4. 10.1111/j.1600-0404.1995.tb01699.x
    1. Palmowski A, Jost WH, Prudlo J, Osterhage J, Kasmann B, Schimrigk K, et al. . Eye movement in amyotrophic lateral sclerosis: a longitudinal study. Ger J Ophthalmol. (1995) 4:355–62.
    1. El Mendili MM, Chen R, Tiret B, Villard N, Trunet S, Pelegrini-Issac M, et al. . Fast and accurate semi-automated segmentation method of spinal cord MR images at 3T applied to the construction of a cervical spinal cord template. PLoS ONE. (2015) 10:e0122224. 10.1371/journal.pone.0122224
    1. Cohen-Adad J, El Mendili MM, Morizot-Koutlidis R, Lehericy S, Meininger V, Blancho S, et al. . Involvement of spinal sensory pathway in ALS and specificity of cord atrophy to lower motor neuron degeneration. Amyotroph Lateral Scler Frontotemporal Degener. (2013) 14:30–8. 10.3109/17482968.2012.701308
    1. Bede P, Bokde AL, Byrne S, Elamin M, Fagan AJ, Hardiman O. Spinal cord markers in ALS: diagnostic and biomarker considerations. Amyotroph Lateral Scler. (2012) 13:407–15. 10.3109/17482968.2011.649760
    1. El Mendili MM, Cohen-Adad J, Pelegrini-Issac M, Rossignol S, Morizot-Koutlidis R, Marchand-Pauvert V, et al. . Multi-parametric spinal cord MRI as potential progression marker in amyotrophic lateral sclerosis. PLoS ONE. (2014) 9:e95516. 10.1371/journal.pone.0095516
    1. Querin G, El Mendili MM, Bede P, Delphine S, Lenglet T, Marchand-Pauvert V, et al. . Multimodal spinal cord MRI offers accurate diagnostic classification in ALS. J Neurol Neurosurg Psychiatry. (2018) 89:1220–1. 10.1136/jnnp-2017-317214
    1. Querin G, El Mendili MM, Lenglet T, Delphine S, Marchand-Pauvert V, Benali H, et al. . Spinal cord multi-parametric magnetic resonance imaging for survival prediction in amyotrophic lateral sclerosis. Eur J Neurol. (2017) 24:1040–6. 10.1111/ene.13329
    1. Grolez G, Moreau C, Danel-Brunaud V, Delmaire C, Lopes R, Pradat PF, et al. . The value of magnetic resonance imaging as a biomarker for amyotrophic lateral sclerosis: a systematic review. BMC Neurol. (2016) 16:155. 10.1186/s12883-016-0672-6
    1. Stroman PW, Wheeler-Kingshott C, Bacon M, Schwab JM, Bosma R, Brooks J, et al. . The current state-of-the-art of spinal cord imaging: methods. NeuroImage. (2014) 84:1070–81. 10.1016/j.neuroimage.2013.04.124
    1. Verma T, Cohen-Adad J. Effect of respiration on the B0 field in the human spinal cord at 3T. Magn Reson Med. (2014) 72:1629–36. 10.1002/mrm.25075
    1. Finegan E, Chipika RH, Shing SLH, Hardiman O, Bede P. Primary lateral sclerosis: a distinct entity or part of the ALS spectrum? Amyotroph Lateral Scler Frontotemporal Degener. 2019:1–13. 10.1080/21678421.2018.1550518
    1. Bede P, Querin G, Pradat PF. The changing landscape of motor neuron disease imaging: the transition from descriptive studies to precision clinical tools. Curr Opin Neurol. (2018) 31:431–8. 10.1097/WCO.0000000000000569
    1. Muller HP, Turner MR, Grosskreutz J, Abrahams S, Bede P, Govind V, et al. . A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. (2016) 87:570–9. 10.1136/jnnp-2015-311952
    1. Atassi N, Xu M, Triantafyllou C, Keil B, Lawson R, Cernasov P, et al. . Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral Sclerosis. PLoS ONE. (2017) 12:e0177680. 10.1371/journal.pone.0177680
    1. Verstraete E, Biessels GJ, van Den Heuvel MP, Visser F, Luijten PR, van Den Berg LH. No evidence of microbleeds in ALS patients at 7 Tesla MRI. Amyotroph Lateral Scler. (2010) 11:555–7. 10.3109/17482968.2010.513053
    1. Dimond D, Ishaque A, Chenji S, Mah D, Chen Z, Seres P, et al. . White matter structural network abnormalities underlie executive dysfunction in amyotrophic lateral sclerosis. Hum Brain Mapp. (2017) 38:1249–68. 10.1002/hbm.23452
    1. Cardenas AM, Sarlls JE, Kwan JY, Bageac D, Gala ZS, Danielian LE, et al. . Pathology of callosal damage in ALS: an ex-vivo, 7 T diffusion tensor MRI study. NeuroImage Clin. (2017) 15:200–8. 10.1016/j.nicl.2017.04.024
    1. De Reuck J, Devos D, Moreau C, Auger F, Durieux N, Deramecourt V, et al. . Topographic distribution of brain iron deposition and small cerebrovascular lesions in amyotrophic lateral sclerosis and in frontotemporal lobar degeneration: a post-mortem 7.0-tesla magnetic resonance imaging study with neuropathological correlates. Acta Neurol Belg. (2017) 117:873–8. 10.1007/s13760-017-0832-5
    1. Pugdahl K, Fuglsang-Frederiksen A, Johnsen B, Tankisi H, de Carvalho M, Fawcett PRW, et al. . Variation in the neurophysiological examination of amyotrophic lateral sclerosis in Europe. Amyotroph Lateral Scler. (2010) 11:443–8. 10.3109/17482960903552496
    1. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. (1999) 169:13–21.
    1. Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 Years of failure. Are we any closer to registering a new treatment? Front Aging Neurosci. (2017) 9:68. 10.3389/fnagi.2017.00068
    1. Jenkinson C, Harris R, Fitzpatrick R. The Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40): evidence for a method of imputing missing data. Amyotroph Lateral Scler. (2007) 8:90–5. 10.1080/17482960600989343
    1. Aggarwal SP, Zinman L, Simpson E, McKinley J, Jackson KE, Pinto H, et al. . Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurology. (2010) 9:481–8. 10.1016/S1474-4422(10)70068-5
    1. Smith R, Pioro E, Myers K, Sirdofsky M, Goslin K, Meekins G, et al. Enhanced bulbar function in amyotrophic lateral sclerosis: the nuedexta treatment trial. Neurotherapeutics. (2017) 14:762–72. 10.1007/s13311-016-0508-5
    1. Woo JH, Wang S, Melhem ER, Gee JC, Cucchiara A, McCluskey L, et al. . Linear associations between clinically assessed upper motor neuron disease and diffusion tensor imaging metrics in amyotrophic lateral sclerosis. PLoS ONE. (2014) 9:e105753. 10.1371/journal.pone.0105753
    1. Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, et al. Efficacy and safety of ceftriaxone for amyotrophic lateral sclerosis: results of a multi-stage, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurology. (2014) 13:1083–91. 10.1016/S1474-4422(14)70222-4
    1. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. (1994) 330:585–91. 10.1056/NEJM199403033300901
    1. Kim S, Kim JK, Son MJ, Kim D, Song B, Son I, et al. . Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial. Trials. (2018) 19:225. 10.1186/s13063-018-2557-z
    1. Shefner JM, Liu D, Leitner ML, Schoenfeld D, Johns DR, Ferguson T, et al. . Quantitative strength testing in ALS clinical trials. Neurology. (2016) 87:617–24. 10.1212/WNL.0000000000002941
    1. Berry JD, Paganoni S, Atassi N, Macklin EA, Goyal N, Rivner M, et al. . Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability. Muscle Nerve. (2017) 56:1077–84. 10.1002/mus.25733
    1. Jawaid A, Murthy SB, Wilson AM, Qureshi SU, Amro MJ, Wheaton M, et al. . A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. Amyotroph Lateral Scler. (2010) 11:542–8. 10.3109/17482968.2010.482592
    1. Calvo A, Moglia C, Lunetta C, Marinou K, Ticozzi N, Ferrante GD, et al. . Factors predicting survival in ALS: a multicenter Italian study. J Neurol. (2017) 264:54–63. 10.1007/s00415-016-8313-y
    1. Abrahams S, Newton J, Niven E, Foley J, Bak TH. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener. (2014) 15:9–14. 10.3109/21678421.2013.805784
    1. Elamin M, Pinto-Grau M, Burke T, Bede P, Rooney J, O'Sullivan M, et al. Identifying behavioural changes in ALS: validation of the Beaumont Behavioural Inventory (BBI). Amyotroph Lateral Scler Frontotemporal Degener. (2016) 8:68–73. 10.1080/21678421.2016.1248976
    1. Woolley SC, York MK, Moore DH, Strutt AM, Murphy J, Schulz PE, et al. . Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS). Amyotroph Lateral Scler. (2010) 11:303–11. 10.3109/17482961003727954
    1. Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B, et al. . Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. (2012) 11:232–40. 10.1016/S1474-4422(12)70014-5
    1. Bede P, Bokde ALW, Byrne S, Elamin M, McLaughlin RL, Kenna K, et al. . Multiparametric MRI study of ALS stratified for the C9orf72 genotype. Neurology. (2013) 81:361–9. 10.1212/WNL.0b013e31829c5eee
    1. Christidi F, Karavasilis E, Rentzos M, Kelekis N, Evdokimidis I, Bede P. Clinical and radiological markers of extra-motor deficits in amyotrophic lateral sclerosis. Front Neurol. (2018) 9:1005. 10.3389/fneur.2018.01005
    1. Burkhardt C, Neuwirth C, Weber M. Longitudinal assessment of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): lack of practice effect in ALS patients? Amyotroph Lateral Scler Frontotemporal Degener. (2017) 18:202–9. 10.1080/21678421.2017.1283418
    1. Kasper E, Zydatiss K, Schuster C, Machts J, Bittner D, Kaufmann J, et al. . No change in executive performance in ALS patients: a longitudinal neuropsychological study. Neurodegener Dis. (2016) 16:184–91. 10.1159/000440957
    1. Woolley S, Goetz R, Factor-Litvak P, Murphy J, Hupf J, Lomen-Hoerth C, et al. . Longitudinal screening detects cognitive stability and behavioral deterioration in ALS patients. Behav Neurol. (2018) 2018:5969137. 10.1155/2018/5969137
    1. Okada M, Yamashita S, Ueyama H, Ishizaki M, Maeda Y, Ando Y. Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis. eNeurologicalSci. (2018) 11:11–4. 10.1016/j.ensci.2018.05.001
    1. Raheja R, Regev K, Healy BC, Mazzola MA, Beynon V, Von Glehn F, et al. . Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. Muscle Nerve. (2018) 58:261–9. 10.1002/mus.26106
    1. Thompson AG, Gray E, Thezenas ML, Charles PD, Evetts S, Hu MT, et al. . Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann Neurol. (2018) 83:258–68. 10.1002/ana.25143
    1. Di Pietro L, Baranzini M, Berardinelli MG, Lattanzi W, Monforte M, Tasca G, et al. . Potential therapeutic targets for ALS: MIR206, MIR208b and MIR499 are modulated during disease progression in the skeletal muscle of patients. Sci Rep. (2017) 7:9538. 10.1038/s41598-017-10161-z
    1. Murdock BJ, Zhou T, Kashlan SR, Little RJ, Goutman SA, Feldman EL. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol. (2017) 74:1446–54. 10.1001/jamaneurol.2017.2255
    1. Shepheard SR, Wuu J, Cardoso M, Wiklendt L, Dinning PG, Chataway T, et al. Urinary p75(ECD): a prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. (2017) 88:1137–43. 10.1212/WNL.0000000000003741
    1. van Eijk RPA, Eijkemans MJC, Ferguson TA, Nikolakopoulos S, Veldink JH, van den Berg LH. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry. (2018) 89:156–61. 10.1136/jnnp-2017-317077
    1. Waller R, Goodall EF, Milo M, Cooper-Knock J, Da Costa M, Hobson E, et al. . Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS). Neurobiol Aging. (2017) 55:123–31. 10.1016/j.neurobiolaging.2017.03.027
    1. McCombe PA, Pfluger C, Singh P, Lim CY, Airey C, Henderson RD. Serial measurements of phosphorylated neurofilament-heavy in the serum of subjects with amyotrophic lateral sclerosis. J Neurol Sci. (2015) 353:122–9. 10.1016/j.jns.2015.04.032
    1. Lu CH, Petzold A, Topping J, Allen K, Macdonald-Wallis C, Clarke J, et al. . Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry. (2015) 86:565–73. 10.1136/jnnp-2014-307672
    1. Levine TD, Bowser R, Hank NC, Gately S, Stephan D, Saperstein DS, et al. . A pilot trial of pioglitazone HCl and tretinoin in ALS: cerebrospinal fluid biomarkers to monitor drug efficacy and predict rate of disease progression. Neurol Res Int. (2012) 2012:582075. 10.1155/2012/582075
    1. Levine TD, Bowser R, Hank N, Saperstein D. A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers. Amyotroph Lateral Scler. (2010) 11:514–9. 10.3109/17482968.2010.513052
    1. Wilson ME, Boumaza I, Lacomis D, Bowser R. Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis. PLoS ONE. (2010) 5:e15133. 10.1371/journal.pone.0015133
    1. Gaiani A, Martinelli I, Bello L, Querin G, Puthenparampil M, Ruggero S, et al. . Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA Neurol. (2017) 74:525–32. 10.1001/jamaneurol.2016.5398
    1. Lu CH, Allen K, Oei F, Leoni E, Kuhle J, Tree T, et al. . Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. (2016) 3:e244. 10.1212/NXI.0000000000000244
    1. Steinacker P, Feneberg E, Weishaupt J, Brettschneider J, Tumani H, Andersen PM, et al. . Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. (2016) 87:12–20. 10.1136/jnnp-2015-311387
    1. Gibson SB, Kasarskis EJ, Hu N, Pulst SM, Mendiondo MS, Matthews DE, et al. . Relationship of creatine kinase to body composition, disease state, and longevity in ALS. Amyotroph Lateral Scler Frontotemporal Degener. (2015) 16:473–7. 10.3109/21678421.2015.1062516
    1. Gray E, Larkin JR, Claridge TD, Talbot K, Sibson NR, Turner MR. The longitudinal cerebrospinal fluid metabolomic profile of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. (2015) 16:456–63. 10.3109/21678421.2015.1053490
    1. Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al. . Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. (2015) 84:2247–57. 10.1212/WNL.0000000000001642
    1. Verstraete E, Kuiperij HB, van Blitterswijk MM, Veldink JH, Schelhaas HJ, van den Berg LH, et al. . TDP-43 plasma levels are higher in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. (2012) 13:446–51. 10.3109/17482968.2012.703208
    1. Nardo G, Pozzi S, Pignataro M, Lauranzano E, Spano G, Garbelli S, et al. . Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS ONE. (2011) 6:e25545. 10.1371/journal.pone.0025545
    1. Steinacker P, Huss A, Mayer B, Grehl T, Grosskreutz J, Borck G, et al. . Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: data from the German MND-net. Amyotroph Lateral Scler Frontotemporal Degener. (2017) 18:112–9. 10.1080/21678421.2016.1241279
    1. Blasco H, Patin F, Descat A, Garcon G, Corcia P, Gele P, et al. . A pharmaco-metabolomics approach in a clinical trial of ALS: identification of predictive markers of progression. PLoS ONE. (2018) 13:e0198116. 10.1371/journal.pone.0198116
    1. Masaldan S, Bush AI, Devos D, Rolland AS, Moreau C. Striking while the iron is hot: iron metabolism and ferroptosis in neurodegeneration. Free Radic Biol Med. (2018) 133:221–33. 10.1016/j.freeradbiomed.2018.09.033
    1. Van Weemen BK, Schuurs AH. Immunoassay using antigen-enzyme conjugates. FEBS Lett. (1971) 15:232–6. 10.1016/0014-5793(71)80319-8
    1. Boylan K, Yang C, Crook J, Overstreet K, Heckman M, Wang Y, et al. . Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem. (2009) 111:1182–91. 10.1111/j.1471-4159.2009.06386.x
    1. Reijn TS, Abdo WF, Schelhaas HJ, Verbeek MM. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol. (2009) 256:615–9. 10.1007/s00415-009-0131-z
    1. Strong MJ, Kesavapany S, Pant HC. The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? J Neuropathol Exp Neurol. (2005) 64:649–64. 10.1097/01.jnen.0000173889.71434.ea
    1. Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, Lacomis D, Urbinelli L, et al. . Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem. (2005) 95:1461–71. 10.1111/j.1471-4159.2005.03478.x
    1. Ryberg H, An J, Darko S, Lustgarten JL, Jaffa M, Gopalakrishnan V, et al. . Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve. (2010) 42:104–11. 10.1002/mus.21683
    1. Pasinetti GM, Ungar LH, Lange DJ, Yemul S, Deng H, Yuan X, et al. . Identification of potential CSF biomarkers in ALS. Neurology. (2006) 66:1218. 10.1212/01.wnl.0000203129.82104.07
    1. Menke RA, Proudfoot M, Wuu J, Andersen PM, Talbot K, Benatar M, et al. . Increased functional connectivity common to symptomatic amyotrophic lateral sclerosis and those at genetic risk. J Neurol Neurosurg Psychiatry. (2016) 87:580–8. 10.1136/jnnp-2015-311945
    1. Carew JD, Nair G, Andersen PM, Wuu J, Gronka S, Hu X, et al. . Presymptomatic spinal cord neurometabolic findings in SOD1-positive people at risk for familial ALS. Neurology. (2011) 77:1370–5. 10.1212/WNL.0b013e318231526a
    1. Lee SE, Sias AC, Mandelli ML, Brown JA, Brown AB, Khazenzon AM, et al. . Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers. NeuroImage Clin. (2017) 14:286–97. 10.1016/j.nicl.2016.12.006
    1. Ng MC, Ho JT, Ho SL, Lee R, Li G, Cheng TS, et al. . Abnormal diffusion tensor in nonsymptomatic familial amyotrophic lateral sclerosis with a causative superoxide dismutase 1 mutation. J Magn Reson Imaging. (2008) 27:8–13. 10.1002/jmri.21217
    1. Wen J, Zhang H, Alexander DC, Durrleman S, Routier A, Rinaldi D, et al. . Neurite density is reduced in the presymptomatic phase of C9orf72 disease. J Neurol Neurosurg Psychiatry. (2018). 10.1136/jnnp-2018-318994. [Epub ahead of print].
    1. Bertrand A, Wen J, Rinaldi D, Houot M, Sayah S, Camuzat A, et al. . Early cognitive, structural, and microstructural changes in presymptomatic C9orf72 carriers younger than 40 Years. JAMA Neurol. (2018) 75:236–45. 10.1001/jamaneurol.2017.4266
    1. Papma JM, Jiskoot LC, Panman JL, Dopper EG, den Heijer T, Donker Kaat L, et al. . Cognition and gray and white matter characteristics of presymptomatic C9orf72 repeat expansion. Neurology. (2017) 89:1256–64. 10.1212/WNL.0000000000004393
    1. Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B. ALSFRS-R score and its ratio: a useful predictor for ALS-progression. J Neurol Sci. (2008) 275:69–73. 10.1016/j.jns.2008.07.016
    1. Rudnicki SA, Berry JD, Ingersoll E, Archibald D, Cudkowicz ME, Kerr DA, et al. . Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler Frontotemporal Degener. (2013) 14:44–51. 10.3109/17482968.2012.723723
    1. Bede P, Iyer PM, Finegan E, Omer T, Hardiman O. Virtual brain biopsies in amyotrophic lateral sclerosis: diagnostic classification based on in vivo pathological patterns. NeuroImage Clin. (2017) 15:653–8. 10.1016/j.nicl.2017.06.010
    1. Bede P, Elamin M, Byrne S, McLaughlin RL, Kenna K, Vajda A, et al. . Patterns of cerebral and cerebellar white matter degeneration in ALS. J Neurol Neurosurg Psychiatry. (2015) 86:468–70. 10.1136/jnnp-2014-308172
    1. Schuster C, Elamin M, Hardiman O, Bede P. The segmental diffusivity profile of amyotrophic lateral sclerosis associated white matter degeneration. Eur J Neurol. (2016) 23:1361–71. 10.1111/ene.13038
    1. Filippini N, Douaud G, Mackay CE, Knight S, Talbot K, Turner MR. Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. Neurology. (2010) 75:1645–52. 10.1212/WNL.0b013e3181fb84d1
    1. Bede P, Bokde A, Elamin M, Byrne S, McLaughlin RL, Jordan N, et al. . Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. J Neurol Neurosurg Psychiatry. (2013) 84:766–73. 10.1136/jnnp-2012-302674
    1. Christidi F, Karavasilis E, Zalonis I, Ferentinos P, Giavri Z, Wilde EA, et al. . Memory-related white matter tract integrity in amyotrophic lateral sclerosis: an advanced neuroimaging and neuropsychological study. Neurobiol Aging. (2017) 49:69–78. 10.1016/j.neurobiolaging.2016.09.014
    1. Bede P, Elamin M, Byrne S, McLaughlin RL, Kenna K, Vajda A, et al. . Basal ganglia involvement in amyotrophic lateral sclerosis. Neurology. (2013) 81:2107–15. 10.1212/01.wnl.0000437313.80913.2c
    1. Bede P, Omer T, Finegan E, Chipika RH, Iyer PM, Doherty MA, et al. . Connectivity-based characterisation of subcortical grey matter pathology in frontotemporal dementia and ALS: a multimodal neuroimaging study. Brain Imaging Behav. (2018) 12:1696–707. 10.1007/s11682-018-9837-9
    1. Agosta F, Ferraro PM, Riva N, Spinelli EG, Domi T, Carrera P, et al. . Structural and functional brain signatures of C9orf72 in motor neuron disease. Neurobiol Aging. (2017) 57:206–19. 10.1016/j.neurobiolaging.2017.05.024
    1. Bede P, Iyer PM, Schuster C, Elamin M, McLaughlin RL, Kenna K, et al. . The selective anatomical vulnerability of ALS: 'disease-defining' and 'disease-defying' brain regions. Amyotroph Lateral Scler Frontotemporal Degener. (2016) 17:561–70. 10.3109/21678421.2016.1173702
    1. Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology. (2009) 73:805–11. 10.1212/WNL.0b013e3181b6bbbd
    1. Loewe K, Machts J, Kaufmann J, Petri S, Heinze HJ, Borgelt C, et al. . Widespread temporo-occipital lobe dysfunction in amyotrophic lateral sclerosis. Sci Rep. (2017) 7:40252. 10.1038/srep40252
    1. Jenkins TM, Alix JJP, David C, Pearson E, Rao DG, Hoggard N, et al. . Imaging muscle as a potential biomarker of denervation in motor neuron disease. J Neurol Neurosurg Psychiatry. (2018) 89:248–55. 10.1136/jnnp-2017-316744
    1. Jongbloed BA, Haakma W, Goedee HS, Bos JW, Bos C, Hendrikse J, et al. . Comparative study of peripheral nerve Mri and ultrasound in multifocal motor neuropathy and amyotrophic lateral sclerosis. Muscle Nerve. (2016) 54:1133–5. 10.1002/mus.25391
    1. de Carvalho M, Chio A, Dengler R, Hecht M, Weber M, Swash M. Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials. Amyotroph Lateral Scler. (2005) 6:17–28. 10.1080/14660820410020600
    1. Rutkove SB. Clinical measures of disease progression in amyotrophic lateral sclerosis. Neurotherapeutics. (2015) 12:384–93. 10.1007/s13311-014-0331-9
    1. Kimura J. Electrodiagnosis in Diseases of Nerve and Muscle: Principles and Practice. Oxford: Oxford University Press; (2001).
    1. Lewelt A, Krosschell KJ, Scott C, Sakonju A, Kissel JT, Crawford TO, et al. . Compound muscle action potential and motor function in children with spinal muscular atrophy. Muscle Nerve. (2010) 42:703–8. 10.1002/mus.21838
    1. Nandedkar SD, Nandedkar DS, Barkhaus PE, Stalberg EV. Motor unit number index (MUNIX). IEEE Trans Biomed Eng. (2004) 51:2209–11. 10.1109/TBME.2004.834281
    1. McComas AJ, Fawcett PR, Campbell MJ, Sica RE. Electrophysiological estimation of the number of motor units within a human muscle. J Neurol Neurosurg Psychiatry. (1971) 34:121–31. 10.1136/jnnp.34.2.121
    1. Neuwirth C, Braun N, Claeys KG, Bucelli R, Fournier C, Bromberg M, et al. . Implementing Motor Unit Number Index (MUNIX) in a large clinical trial: real world experience from 27 centres. Clin Neurophysiol. (2018) 129:1756–62. 10.1016/j.clinph.2018.04.614
    1. Fastenau PS, Denburg NL, Mauer BA. Parallel short forms for the Boston Naming Test: psychometric properties and norms for older adults. J Clin Exp Neuropsychol. (1998) 20:828–34. 10.1076/jcen.20.6.828.1105
    1. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, et al. . Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. (2008) 79:33–7. 10.1136/jnnp.2007.118018
    1. Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. . Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. (2009) 10:310–23. 10.3109/17482960802566824
    1. Elamin M, Phukan J, Bede P, Jordan N, Byrne S, Pender N, et al. . Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology. (2011) 76:1263–9. 10.1212/WNL.0b013e318214359f
    1. Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve. (2002) 25:709–14. 10.1002/mus.10090
    1. Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. (2018) 7:423–33. 10.1016/S1474-4422(18)30089-9
    1. Schuster C, Hardiman O, Bede P. Survival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics. BMC Neurol. (2017) 17:73. 10.1186/s12883-017-0854-x
    1. Capozzo R, Quaranta VN, Pellegrini F, Fontana A, Copetti M, Carratu P, et al. Sniff nasal inspiratory pressure as a prognostic factor of tracheostomy or death in amyotrophic lateral sclerosis. J Neurol. (2015) 262:593–603. 10.1007/s00415-014-7613-3
    1. Polkey MI, Lyall RA, Yang K, Johnson E, Leigh PN, Moxham J. Respiratory muscle strength as a predictive biomarker for survival in amyotrophic lateral sclerosis. Am J Respir Crit Care Med. (2017) 195:86–95. 10.1164/rccm.201604-0848OC
    1. Gordon PH, Salachas F, Lacomblez L, Le Forestier N, Pradat PF, Bruneteau G, et al. . Predicting survival of patients with amyotrophic lateral sclerosis at presentation: a 15-year experience. Neurodegener Dis. (2013) 12:81–90. 10.1159/000341316
    1. Kalra S, Vitale A, Cashman NR, Genge A, Arnold DL. Cerebral degeneration predicts survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. (2006) 77:1253–5. 10.1136/jnnp.2006.090696
    1. Agosta F, Pagani E, Petrolini M, Sormani MP, Caputo D, Perini M, et al. . MRI predictors of long-term evolution in amyotrophic lateral sclerosis. Eur J Neurosci. (2010) 32:1490–6. 10.1111/j.1460-9568.2010.07445.x
    1. Pinto S, Pinto A, de Carvalho M. Phrenic nerve studies predict survival in amyotrophic lateral sclerosis. Clin Neurophysiol. (2012) 123:2454–9. 10.1016/j.clinph.2012.05.012
    1. Pijnenburg YA, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement. (2015) 1:505–12. 10.1016/j.dadm.2015.11.001
    1. Oberstadt M, Classen J, Arendt T, Holzer M. TDP-43 and cytoskeletal proteins in ALS. Mol Neurobiol. (2018) 55:3143–51. 10.1007/s12035-017-0543-1
    1. Ganesalingam J, An J, Shaw CE, Shaw G, Lacomis D, Bowser R. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem. (2011) 117:528–37. 10.1111/j.1471-4159.2011.07224.x
    1. Paganoni S, Macklin EA, Lee A, Murphy A, Chang J, Zipf A, et al. . Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Frontotemporal Degener. (2014) 15:453–6. 10.3109/21678421.2014.903974
    1. Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, et al. . Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurology. (2013) 12:1059–67. 10.1016/S1474-4422(13)70221-7
    1. Kernan WN, Viscoli CM, Makuch RW, Brass LM, Horwitz RI. Stratified randomization for clinical trials. J Clin Epidemiol. (1999) 52:19–26. 10.1016/S0895-4356(98)00138-3
    1. Nicholson KA, Cudkowicz ME, Berry JD. Clinical trial designs in amyotrophic lateral sclerosis: does one design fit all? Neurotherapeutics. (2015) 12:376–83. 10.1007/s13311-015-0341-2
    1. Miller TM, Smith RA, Kordasiewicz H, Kaspar BK. Gene-targeted therapies for the central nervous system. Arch Neurol. (2008) 65:447–51. 10.1001/archneur.65.4.nnr70007
    1. Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, Li HR, et al. . Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci USA. (2013) 110:E4530–9. 10.1073/pnas.1318835110
    1. Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, et al. . A proposed staging system for amyotrophic lateral sclerosis. Brain. (2012) 135(Pt 3):847–52. 10.1093/brain/awr351
    1. Chio A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. (2015) 86:38–44. 10.1136/jnnp-2013-306589
    1. Thakore NJ, Lapin BR, Kinzy TG, Pioro EP. Deconstructing progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach. Amyotroph Lateral Scler Frontotemporal Degener. (2018) 19:483–494. 10.1080/21678421.2018.1484925
    1. Fang T, Al Khleifat A, Stahl DR, Lazo La Torre C, Murphy C, Uk-Mnd Lical S, et al. . Comparison of the King's and MiToS staging systems for ALS. Amyotroph Lateral Scler Frontotemporal Degener. (2017) 18:227–32. 10.1080/21678421.2016.1265565
    1. Tramacere I, Dalla Bella E, Chio A, Mora G, Filippini G, Lauria G. The MITOS system predicts long-term survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. (2015) 86:1180–5. 10.1136/jnnp-2014-310176
    1. Braak H, Brettschneider J, Ludolph AC, Lee VM, Trojanowski JQ, Del Tredici K. Amyotrophic lateral sclerosis–a model of corticofugal axonal spread. Nat Rev Neurol. (2013) 9:708–14. 10.1038/nrneurol.2013.221
    1. Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al. . Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. (2013) 74:20–38. 10.1002/ana.23937
    1. Kassubek J, Muller HP, Del Tredici K, Brettschneider J, Pinkhardt EH, Lule D, et al. . Diffusion tensor imaging analysis of sequential spreading of disease in amyotrophic lateral sclerosis confirms patterns of TDP-43 pathology. Brain. (2014) 137(Pt 6):1733–40. 10.1093/brain/awu090
    1. Sherman AV, Gubitz AK, Al-Chalabi A, Bedlack R, Berry J, Conwit R, et al. . Infrastructure resources for clinical research in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. (2013) 14(Suppl. 1):53–61. 10.3109/21678421.2013.779058
    1. Sherman A, Bowser R, Grasso D, Power B, Milligan C, Jaffa M, et al. . Proposed BioRepository platform solution for the ALS research community. Amyotroph Lateral Scler. (2011) 12:11–6. 10.3109/17482968.2010.539233
    1. Otto M, Bowser R, Turner M, Berry J, Brettschneider J, Connor J, et al. . Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler. (2012) 13:1–10. 10.3109/17482968.2011.627589
    1. Turner MR, Grosskreutz J, Kassubek J, Abrahams S, Agosta F, Benatar M, et al. . Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol. (2011) 10:400–3. 10.1016/S1474-4422(11)70049-7
    1. Johnston MV, Adams HP, Fatemi A. Neurobiology of Disease. Oxford: Oxford University Press; (2016).
    1. Northeast ALS Consortium . NEALS Member Sites. Available online at:
    1. Beghi E. 127th ENMC International Workshop: implementation of a European registry of ALS. Naarden, The Netherlands, 8-10 October 2004. Neuromuscul Disord. (2006) 16:46–53. 10.1016/j.nmd.2005.10.004
    1. Beghi E, Logroscino G, Chio A, Hardiman O, Mitchell D, Swingler R, et al. . The epidemiology of ALS and the role of population-based registries. Biochim Biophys Acta. (2006) 1762:1150–7. 10.1016/j.bbadis.2006.09.008
    1. Hobson EV, Baird WO, Partridge R, Cooper CL, Mawson S, Quinn A, et al. . The TiM system: developing a novel telehealth service to improve access to specialist care in motor neurone disease using user-centered design. Amyotroph Lateral Scler Frontotemporal Degener. (2018) 19:351–61. 10.1080/21678421.2018.1440408
    1. Geronimo A, Wright C, Morris A, Walsh S, Snyder B, Simmons Z. Incorporation of telehealth into a multidisciplinary ALS Clinic: feasibility and acceptability. Amyotroph Lateral Scler Frontotemporal Degener. (2017) 18:555–61. 10.1080/21678421.2017.1338298
    1. Christodoulou G, Gennings C, Hupf J, Factor-Litvak P, Murphy J, Goetz RR, et al. . Telephone based cognitive-behavioral screening for frontotemporal changes in patients with amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Frontotemporal Degener. (2016) 17:482–8. 10.3109/21678421.2016.1173703

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere